Sbir phase i: autonomous system for DNA sequencing prep in space and austere environments

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of an autonomous, miniaturized system for DNA extraction and preparation for sequencing. The $275,000 award to Anyglabs, Inc. will fund the creation of a portable, automated device capable of high-throughput DNA processing in space and other austere environments. The goal is to democratize access to advanced molecular diagnostics by enabling widespread use of DNA sequencing for medical, environmental, and security applications, even in remote or under-resourced regions. This work aims to leverage the microgravity environment of space to advance biotechnology innovation, while also providing solutions for terrestrial settings lacking infrastructure for current DNA sequencing technologies. The project will run from March 2024 through February 2025.

Abstract

The broader impact/commercial potential of this small business innovation research (sbir) project is to democratize access to advanced diagnostics tools by building an automated, miniaturized system for DNA extraction and preparation for sequencing for both in space and austere environments. This automated and miniaturized approach has the potential to contribute to a higher throughput acceleration of in-space r & d, manufacturing, and commercialization for biotechnology. DNA sequencing is used for various purposes in research and medicine ? For example, diagnosis and treatment of diseases, monitoring of pathogens in water supplies and food, and study of the effects of the environment on human, crop, and pet health. Yet nearly 50% of the world?s population has little or no access to such advanced diagnostics tools, and at least 2.2 billion people lacked safe drinking water in 2022. Even though there is high interest in genetic testing among individuals of low socioeconomic status, such tests are inaccessible due to cost or availability. The global DNA sequencing market size of $11B in 2022 is expected to grow to over $50B by 2032. This project is disrupting the status QUO and addressing an unserved market by developing a small, portable, automated, high throughput, and cost-effective system for extracting DNA from a variety of biosamples to prepare them for next-generation sequencing. The in-space environment has the potential to leverage microgravity advantages for a wide range of biotechnology-based advances but is currently capacity and throughput-constrained. This project will further accelerate a high-throughput, faster iterative approach to in-space r & d to achieve more of the disruptive solutions possible from microgravity. This sbir phase i project proposes a unique approach to technology development ? Building the technology for space and microgravity, the most extreme environment. Currently, no such automated, miniaturized technology exists in space for DNA extraction and sample preparation. Space is a unique environment that can offer novel scientific insights. The availability of advanced tools in microgravity, such as the technology proposed in this project, will enable scientists to push the boundaries of knowledge across a variety of disciplines, from aging and longevity research to cancer medicines to stem cell expansion and organoid production in space. Furthermore, by solving for space ? An extreme, harsh environment with many constraints ? The technology will also solve for earth?s austere environments and provide a high-caliber diagnostic system for populations in remote, underserved, under-resourced, and extreme environments, which includes military field operations for national defense and security. This technology is pushing the boundaries of scientific discovery in space and democratizing health and welfare on earth. The first product is only the beginning of a series of products for portable advanced end-point-analysis tools. The platform technology will spin off subsequent devices that will eventually enable in-home or point-of-care diagnostics. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.